THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to ...
Amgen (AMGN) announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha. This follows landmark results demonstrating Repatha significantly reduced the risk of major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback